Zealand’s diabetes-hope recommended for approval
The diabetes drug Lyxumia, developed by Danish company Zealand Pharma and pharmaceutical giant Sanofi, has been recommended for approval by the EMA’s medical committee.
by Stefan Singh Kailay
Lyxumia, a GLP-1 analogue used for treating diabetes, has moved one step closer to the European market; the Victoza-rival has been recommended for approval by the CHMP, a medical committee under the European Medicines Agency (EMA).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
